{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:56Z","timestamp":1792620836893,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jchf.2023.09.015","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:57:15Z","timestamp":1696629435000},"page":"248-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Applications of Gene Therapy in\u00a0Cardiomyopathies"],"prefix":"10.1016","volume":"12","author":[{"given":"Alessia","family":"Argiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly N.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1676-5257","authenticated-orcid":false,"given":"Enrico","family":"Ammirati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jchf.2023.09.015_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvv205","article-title":"Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation","volume":"108","author":"Rincon","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2023.09.015_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-genom-111221-103208","article-title":"Diverse molecular mechanisms underlying pathogenic protein mutations: beyond the loss-of-function paradigm","volume":"23","author":"Backwell","year":"2022","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"1","key":"10.1016\/j.jchf.2023.09.015_bib3","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1038\/s41467-022-31686-6","article-title":"Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure","volume":"13","author":"Gerasimavicius","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jchf.2023.09.015_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.emboj.7601977","article-title":"Messenger RNA regulation: to translate or to degrade","volume":"27","author":"Shyu","year":"2008","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.jchf.2023.09.015_bib5","doi-asserted-by":"crossref","first-page":"H629","DOI":"10.1152\/ajpheart.00126.2012","article-title":"Nonviral gene therapy targeting cardiovascular system","volume":"303","author":"Su","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.jchf.2023.09.015_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50980-w","article-title":"Non-viral vector based gene transfection with human induced pluripotent stem cells derived cardiomyocytes","volume":"9","author":"Tan","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jchf.2023.09.015_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","article-title":"Targeted delivery of therapeutic agents to the heart","volume":"18","author":"Sahoo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2023.09.015_bib8","series-title":"Genome Editing in Cardiovascular and Metabolic Diseases","first-page":"3","article-title":"An overview of genome editing in cardiovascular and metabolic diseases","author":"Musunuru","year":"2023"},{"issue":"3","key":"10.1016\/j.jchf.2023.09.015_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/ijms21030733","article-title":"Genome editing for the understanding and treatment of inherited cardiomyopathies","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jchf.2023.09.015_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.stem.2013.03.006","article-title":"Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs","volume":"12","author":"Ding","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.jchf.2023.09.015_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jchf.2023.09.015_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jchf.2023.09.015_bib13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity\u2014\u2018one and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jchf.2023.09.015_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105332","article-title":"Adeno-associated virus (AAV)-based gene therapy products: What are toxicity studies in non-human primates showing us?","volume":"138","author":"Baldrick","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"issue":"24","key":"10.1016\/j.jchf.2023.09.015_bib15","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jchf.2023.09.015_bib16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.gt.3303020","article-title":"Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts","volume":"14","author":"McTiernan","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.jchf.2023.09.015_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1094279","article-title":"Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase","volume":"14","author":"Hordeaux","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jchf.2023.09.015_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.jchf.2023.09.015_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Abstract 10727: Results from first-in-human clinical trial of RP-A501 (AAV9:LAMP2B) gene therapy treatment for Danon disease","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2023.09.015_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jchf.2023.09.015_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Aus Dem Siepen F, Donal E, et\u00a0al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jchf.2023.09.015_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus\u2013mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.jchf.2023.09.015_bib28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jchf.2023.09.015_bib29","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.jchf.2023.09.015_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jchf.2023.09.015_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in\u00a0vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2023.09.015_bib32","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.jchf.2023.09.015_bib33","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","article-title":"Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations","volume":"72","author":"Dom\u00ednguez","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jchf.2023.09.015_bib34","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1038\/s41467-021-23272-z","article-title":"Cardiomyocyte contractile impairment in heart failure\u00a0results from reduced BAG3-mediated sarcomeric protein turnover","volume":"12","author":"Martin","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jchf.2023.09.015_bib35","first-page":"951","article-title":"Cardiac transduction in mini-pigs after low-dose retrograde coronary sinus infusion of AAV9-BAG3","volume":"7","author":"Myers","year":"2022","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jchf.2023.09.015_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/circ.146.suppl_1.13599","article-title":"Abstract 13599: LX2020, an adeno associated viral-based plakophilin 2 gene therapy stabilizes cardiac disease phenotype in a severe mouse model of arrhythmogenic right ventricular cardiomyopathy","volume":"146","author":"Sheikh","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jchf.2023.09.015_bib37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/cr.2016.101","article-title":"Genome editing with CRISPR\/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome","volume":"26","author":"Xie","year":"2016","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.jchf.2023.09.015_bib38","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep"},{"issue":"7965","key":"10.1016\/j.jchf.2023.09.015_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/d41586-023-01799-z","article-title":"\u2018It\u2019s a vote for hope\u2019: first gene therapy for muscular dystrophy nears approval, but will it work?","volume":"618","author":"Reardon","year":"2023","journal-title":"Nature"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923006248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923006248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:05:02Z","timestamp":1761973502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923006248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2213177923006248"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.09.015","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications of Gene Therapy in\u00a0Cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}